IAS–USA Board of Directors Disclosure Information

The non-staff members of the IAS–USA Board of Directors participate in a volunteer capacity. They are not compensated for their role in governing/overseeing the IAS–USA

In accordance with IAS–USA policy on disclosure and conflicts of interest, information regarding conflicts of interest is obtained from all parties with control over activity content (ie, directors, officers, activity chairs, faculty, authors, and IAS–USA staff), and conflicts of interest of those parties are resolved.

Below are the financial interests that the volunteer members of the Board of Directors have had with commercial companies within the last 12 months of the date of disclosure (noted next to each):

Dr Benson has no relevant financial affiliations to disclose. (Updated 10/03/11)

Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc. (Updated 10/03/11)

Dr del Rio has received research grants awarded to Emory University from Merck & Co, Inc, Schering-Plough Corp (now Merck & Co, Inc), and Sanofi Pasteur and has served as a consultant to Gilead Sciences, Inc. (Updated 09/27/11)

Dr Gallant has served as a consultant to or advisor to Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Janssen Therapeutics, RAPID Pharmaceuticals, and Sangamo Bioscience. Johns Hopkins University has been the recipient of research grants or contracts from Gilead Sciences, Inc. (Updated 09/28/11)

Dr Gulick has received grants and research support from Merck & Co, Inc, Pfizer Inc, Tibotec Therapeutics, ViiV Healthcare, and Vircostatics. He has served as a consultant to Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Tibotec Therapeutics, ViiV Healthcare, and ViroStatics. He has received travel, accommodations, or meeting expenses related or unrelated to activities listed from Bristol-Myers Squibb, Gilead Sciences, Merck & Co, Inc, Tibotec Therapeutics, ViiV Healthcare, and Virostatics. (Updated 09/07/11)

Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 10/14/11)

Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, Chemerix, Gen-Probe Inc, Gilead Sciences, Inc, Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc. He has been the recipient of research grants or contracts from Merck & Co, Inc. Dr Richman has been a stock options holder of Chemerix. (Updated 09/28/11)

Dr Saag has received grants and research support from and/or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 10/04/11)

Dr Schooley has served as a consultant to Gilead Sciences, Inc, Inhibitex, Inc, Johnson & Johnson Services, Inc, Laboratory Corporation of America, Merck & Co, Inc, Santaris Pharma, and Tobira Therapeutics. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 09/28/11)

Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb, and Gilead Sciences, Inc. He has served on data and safety monitoring boards for Gilead Sciences, Inc. (Updated 09/28/11)